SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Himax Reports Q3 2026 Results and Issues Q4 Guidance

Q3 2026 EPS exceeded guidance, while revenue and gross margin were in line with guidance issued Aug. 6, 2026.

HIMX
SquawkNews Desk 3 updates Updated Nov 05, 2026, 11:49 AM UTC

Story updates

11:37:56 AM UTC
SquawkNews
HIMAX TECHNOLOGIES Q3 GROSS MARGIN 34.2%
11:38:23 AM UTC
SquawkNews
HIMAX TECHNOLOGIES, INC. REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS; PROVIDES FOURTH QUARTER 2026
11:49:48 AM UTC
SquawkNews
Taiwan's Himax Q3 profit tops guidance, Q4 revenue to drop 22-26%

Related stories

Zoetis Reports Q3 Results, Narrows Revenue Guidance and Raises EPS Outlook Zoetis reported third-quarter revenue of $2.4 billion, down 1% reported and organic operationally. The company narrowed its full-year 2026 revenue guidance and raised its adjusted M impact | EQUITY | Nov 05, 2026, 12:08 PM UTC Trian Seeks to Acquire Wendy’s for $7.35 per Share Trian Group seeks to acquire all outstanding Wendy’s common shares for $7.35 per share in cash. M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC Shift4 Announces Third-Quarter 2026 Results Shift4 has posted its third-quarter 2026 financial results. M impact | EQUITY | Nov 05, 2026, 12:03 PM UTC 1stDibs Reports Third-Quarter 2026 Results M impact | EQUITY | Nov 05, 2026, 12:03 PM UTC ConocoPhillips Reports Q3 Results, Raises Quarterly Dividend 11% ConocoPhillips reported third-quarter 2026 EPS of $3.34 and adjusted EPS of $3.27, and increased its quarterly ordinary dividend by 11%. M impact | EQUITY | Nov 05, 2026, 12:03 PM UTC C4 Therapeutics Reports Third-Quarter 2026 Results and Trial Update The company said enrollment in its Phase 2 MOMENTUM trial of cemsidomide remains on track to finish in the first quarter of 2027, with initial ORR data expected. M impact | EQUITY | Nov 05, 2026, 12:03 PM UTC